- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Development of mRNA.encoded NK cell engager for the treatment of relapsed/refractory B cell lymphoma | ||||||
| Nucleic acid/Virus | B cell lymphoma | NK cell | Hit | De novo Biotherapeutics | RS-2023-00258675 | ||
| 2 | Candidate selection of a first.in.class RNA therapeuticfor the treatment of BRAF mutant pediatric brain tumors | ||||||
| Nucleic acid/Virus | Pediatric brain tumor | BRAF | Candidate | Sovargen | RS-2023-00258484 | ||